Lilly’s “normal” 483
Executive Summary
Lilly receives FDA 483 report "as part of the normal inspection process" for its dry and injectable facilities in Indianapolis. Company says that the outcome of the inspection is not expected to delay the expected fourth quarter launch of the antidepressant Cymbalta, which is manufactured at the dry facility. Inspection ran from May 5-23; the 483 was issued on May 29. Lilly has said that it expects FDA will judge its facilities based on the company's GMP progress rather than its absolute compliance (1"The Pink Sheet" April 28, 2003, p. 31)...
You may also be interested in...
Lilly GMPs Will Not Deter Product Rollout, Firm Says
The remaining Lilly products delayed by good manufacturing practices compliance problems could be approved by FDA before the company has fully implemented its GMP improvement program
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.